Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17776024 | 0.91 | — | — | |
| SCHEMBL8721084 | 0.87 | — | — | |
| SCHEMBL10717108 | 0.87 | — | — | |
| SCHEMBL9177881 | 0.83 | CYP2C19 (0.36) | CA2TSHRTDP1 | |
| SCHEMBL17469828 | 0.83 | CA2 (0.33) | CA2TSHRTDP1 | |
| Ammonia Solution, Strong SCHEMBL28099420 | 0.81 | CYP2C19 (0.35) | CA2 | |
| SCHEMBL12533296 | 0.81 | CA2 (0.32) | CA2 | |
| Hydrochloric Acid SCHEMBL29798815 | 0.81 | CYP2C19 (0.35) | CA2 | |
| SCHEMBL4839340 | 0.79 | CA2 (0.30) | CA2 | |
| SCHEMBL4611122 | 0.79 | CA2 (0.31) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999045947-A9 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2000-03-02 | — | — | WO | claimed |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140135403-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2014-05-15 | — | — | US | disclosed |
| EP-2656839-A1 | Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases | Waratah Pharmaceuticals, Inc. (CA) | 2013-10-30 | — | — | EP | disclosed |
| US-20110105626-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | MCLAURIN JOANNE | 2011-05-05 | — | — | US | disclosed |
| US-20100331267-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | MCLAURIN JOANNE | 2010-12-30 | — | — | US | disclosed |
| US-20100292157-A1 | Combination Treatments for Alzheimer's Disease and Similar Diseases | WARATAH PHARMACEUTICALS INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| US-20100173960-A1 | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases | WARATAH PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | US | disclosed |
| US-20100168250-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASE | WARATAH PHARMACEUTICALS INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100144891-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | MCLAURIN JOANNE | 2010-06-10 | — | — | US | disclosed |
| EP-1940373-A2 | INOSITOL DERIVATIVES AND THEIR USES IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DESPOSITION, ACCUMULATION OR PERSISTENCE | Waratah Pharmaceuticals, Inc. (CA) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008061373-A1 | COMBINATION TREATMENTS FOR ALZHEIMER'S DISEASE AND SIMILAR DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008034244-A1 | THE COMBINATION OF A CYCLOHEXANEHEXOL AND A NSAID FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007119108-A2 | INOSITOL DERIVATIVES AND THEIR USES IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| US-7148001-B2 | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases | UNIVERSITY OF WASHINGTON (US) | 2006-12-12 | — | — | US | disclosed |
| US-20020168753-A1 | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases | NATIONAL INSTITUTES OF HEALTH | 2002-11-14 | — | — | US | disclosed |
| EP-1054664-A1 | METHOD FOR MODULATING MACROPHAGE ACTIVATION | Neurochem, Inc. (CA) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999045947-A9 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999040909-A1 | METHOD FOR MODULATING MACROPHAGE ACTIVATION | NEUROCHEM, INC. (CA) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331267-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | SNCA, PARK7, PMP22 | CA2 2600/4885TSHR 4348/4885TDP1 1908/4885 |
| US-20110105626-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | CDR2, HYPK, HTT | CA2 4000/4885TSHR 2538/4885TDP1 1100/4885 |
| US-20100168250-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASE | APP, IAPP, TTR | CA2 1036/4885TSHR 1251/4885TDP1 2467/4885 |
| US-20100292157-A1 | Combination Treatments for Alzheimer's Disease and Similar Diseases | APP, PSEN1, BACE1 | CA2 1837/4885TSHR 4811/4885TDP1 370/4885 |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | SCLY, SMOX, SMS | CA2 1937/4885TSHR 468/4885TDP1 3399/4885 |
| US-20100173960-A1 | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases | HTT, APP, PSEN2 | CA2 1438/4885TSHR 4731/4885TDP1 470/4885 |
| US-20140135403-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | APP, IAPP, TTR | CA2 1094/4885TSHR 1412/4885TDP1 2475/4885 |
| US-20100144891-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SOD1, SOD3, SMN1; SMN2 | CA2 886/4885TSHR 3913/4885TDP1 2051/4885 |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | SCLY, SCO2, SGMS2 | CA2 2349/4885TSHR 703/4885TDP1 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.